268 related articles for article (PubMed ID: 30507318)
1. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis.
Maschio M; Pauletto G; Zarabla A; Maialetti A; Ius T; Villani V; Fabi A; Koudriavtseva T; Giannarelli D
Int J Neurosci; 2019 Jun; 129(6):593-597. PubMed ID: 30507318
[TBL] [Abstract][Full Text] [Related]
2. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
3. Perampanel in brain tumor-related epilepsy: Observational pilot study.
Maschio M; Zarabla A; Maialetti A; Giannarelli D; Koudriavtseva T; Villani V; Zannino S
Brain Behav; 2020 Jun; 10(6):e01612. PubMed ID: 32285623
[TBL] [Abstract][Full Text] [Related]
4. Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel.
Izumoto S; Miyauchi M; Tasaki T; Okuda T; Nakagawa N; Nakano N; Kato A; Fujita M
Anticancer Res; 2018 Jul; 38(7):4361-4366. PubMed ID: 29970574
[TBL] [Abstract][Full Text] [Related]
5. Perampanel in brain tumor and SMART-syndrome related epilepsy - A single institutional experience.
Heugenhauser J; Iglseder S; Muigg A; Kerschbaumer J; Stockhammer G; Nowosielski M; Unterberger I
J Neurol Sci; 2021 Apr; 423():117386. PubMed ID: 33706200
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
7. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
[TBL] [Abstract][Full Text] [Related]
8. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.
Vecht C; Duran-Peña A; Houillier C; Durand T; Capelle L; Huberfeld G
J Neurooncol; 2017 Jul; 133(3):603-607. PubMed ID: 28492978
[TBL] [Abstract][Full Text] [Related]
9. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
[TBL] [Abstract][Full Text] [Related]
10. Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data.
Rohracher A; Zimmermann G; Villanueva V; Garamendi I; Sander JW; Wehner T; Shankar R; Ben-Menachem E; Brodie MJ; Pensel MC; Di Gennaro G; Maurousset A; Strzelczyk A; Rheims S; Rácz A; Menzler K; Bertol-Alegre V; García-Morales I; López-González FJ; Toledo M; Carpenter KJ; Trinka E
Epilepsia; 2018 Sep; 59(9):1727-1739. PubMed ID: 30047129
[TBL] [Abstract][Full Text] [Related]
11. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
[TBL] [Abstract][Full Text] [Related]
13. NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy.
Villanueva V; Saiz-Diaz R; Toledo M; Piera A; Mauri JA; Rodriguez-Uranga JJ; López-González FJ; Gómez-Ibáñez A; Garcés M; González de la Aleja J; Rodríguez-Osorio X; Palao-Duarte S; Castillo A; Bonet M; Ruiz-Giménez J; Palau J; Arcediano A; Toledo M; Gago A
Epilepsy Behav; 2016 Dec; 65():25-32. PubMed ID: 27863278
[TBL] [Abstract][Full Text] [Related]
14. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
15. Preliminary Asian experience of using perampanel in clinical practice.
Chiang HI; Lim SN; Hsieh HY; Cheng MY; Chang CW; Johnny Tseng WE; Li HT; Lin CY; Wu T
Biomed J; 2017 Dec; 40(6):347-354. PubMed ID: 29433838
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center.
Kurth C; Kockelmann E; Steinhoff BJ
Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
20. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
